Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
DRI Healthcare ( ($TSE:DHT.UN) ) has provided an update.
DRI Healthcare Trust announced the results of its annual general meeting, where all trustee nominees were elected, and Deloitte LLP was reappointed as auditors. The reappointment of Deloitte LLP as auditors received strong support, with 95.75% of votes in favor, reflecting confidence in the Trust’s governance and financial oversight.
The most recent analyst rating on ($TSE:DHT.UN) stock is a Buy with a C$20.00 price target. To see the full list of analyst forecasts on DRI Healthcare stock, see the TSE:DHT.UN Stock Forecast page.
Spark’s Take on TSE:DHT.UN Stock
According to Spark, TipRanks’ AI Analyst, TSE:DHT.UN is a Neutral.
DRI Healthcare Trust’s strong balance sheet and effective cash flow management are overshadowed by profitability challenges due to revenue decline and net losses. Technical analysis shows a bearish trend, and valuation concerns arise from negative earnings. However, recent corporate events indicate a positive outlook with improved financial results and strategic management, providing a moderate boost to the overall score.
To see Spark’s full report on TSE:DHT.UN stock, click here.
More about DRI Healthcare
DRI Healthcare Trust is managed by DRI Capital Inc., a leader in global pharmaceutical royalty monetization. Since its IPO in 2021, the Trust has invested over $1 billion, acquiring more than 25 royalties on over 20 drugs, including Eylea, Orserdu, Omidria, Spinraza, Stelara, Vonjo, Zejula, and Zytiga. Its units are traded on the Toronto Stock Exchange in both Canadian and U.S. dollars.
Average Trading Volume: 35,885
Technical Sentiment Signal: Buy
Current Market Cap: C$698.3M
For detailed information about DHT.UN stock, go to TipRanks’ Stock Analysis page.